Log in

NASDAQ:PRTAProthena Stock Price, Forecast & News

$10.66
-0.45 (-4.05 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.41
Now: $10.66
$11.17
50-Day Range
$10.65
MA: $11.56
$12.31
52-Week Range
$6.71
Now: $10.66
$17.63
Volume432,666 shs
Average Volume225,974 shs
Market Capitalization$425.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Read More
Prothena logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRTA
CUSIPN/A
Phone011-353-1236-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$810,000.00
Book Value$6.39 per share

Profitability

Net Income$-77,680,000.00
Net Margins-10,452.67%

Miscellaneous

Employees59
Market Cap$425.44 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Prothena (NASDAQ:PRTA) Frequently Asked Questions

How has Prothena's stock been impacted by COVID-19 (Coronavirus)?

Prothena's stock was trading at $9.72 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRTA stock has increased by 9.7% and is now trading at $10.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Prothena?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Prothena.

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Prothena.

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.02. The biotechnology company earned $0.14 million during the quarter, compared to analysts' expectations of $0.23 million. Prothena had a negative return on equity of 28.71% and a negative net margin of 10,452.67%. View Prothena's earnings history.

What price target have analysts set for PRTA?

5 analysts have issued 1-year price targets for Prothena's stock. Their forecasts range from $9.00 to $19.00. On average, they expect Prothena's share price to reach $15.25 in the next twelve months. This suggests a possible upside of 43.1% from the stock's current price. View analysts' price targets for Prothena.

Has Prothena been receiving favorable news coverage?

Media coverage about PRTA stock has been trending positive on Sunday, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Prothena earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutProthena.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.49%), State Street Corp (2.64%), Wellington Management Group LLP (2.33%), Geode Capital Management LLC (1.48%), Nuveen Asset Management LLC (1.28%) and Rock Springs Capital Management LP (1.25%). View institutional ownership trends for Prothena.

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Squarepoint Ops LLC, JPMorgan Chase & Co., Pinnacle Associates Ltd., Wellington Management Group LLP, Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., and UBS Group AG. View insider buying and selling activity for Prothena.

Which institutional investors are buying Prothena stock?

PRTA stock was bought by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Nuveen Asset Management LLC, Acadian Asset Management LLC, AXA, Morgan Stanley, Systematic Financial Management LP, Geode Capital Management LLC, and Los Angeles Capital Management & Equity Research Inc.. View insider buying and selling activity for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $10.66.

How big of a company is Prothena?

Prothena has a market capitalization of $425.44 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-77,680,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Prothena employs 59 workers across the globe.

What is Prothena's official website?

The official website for Prothena is www.prothena.com.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.